Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Market Movers
TipRanks 50 Index
AI Stocks
Largest Companies by Market Cap
ETFs
Top ETFs by Upside
Top ETFs by Smart Score
Top Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Ideas
Plans
Research Tools
Trending Stocks
Compare Stocks
Compare ETFs
Trump Dashboard
New
Daily Feeds
Daily Analyst Ratings
Daily Insider Trading Tracker
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
FDA Calendar
Market Holidays
Calculators
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Economic Indicators
Inflation Rate
Unemployment Rate
Class Actions
Tools
Plans
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Screeners
Plans
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Dividends
Plans
My Experts
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Experts
Plans
Portfolio
Plans
Trending News
More News >
News
Plans
Private Companies
Plans
Enterprise Solutions
Plans
Education
Personal Finance
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Careers
Contact Us
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Advertise with Us
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
More
Plans
Plans
Plans
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Screeners
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Ideas
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Research Tools
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Calculators
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
FDA Calendar
Market Holidays
Dividends
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Experts
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Market Movers
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Private Companies
Personal Finance
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
More
Education
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Log Out
Advertisement
Advertisement
KYMR
Stock Latest News
The Fly
Kymera Therapeutics initiated with a Buy at Canaccord
19d ago
KYMR
Premium
The Fly
Kymera Therapeutics initiated with a Buy at Canaccord
19d ago
KYMR
Premium
The Fly
AMD upgraded, Reddit downgraded: Wall Street’s top analyst calls
19d ago
BX
FG
Premium
The Fly
Kymera Therapeutics price target lowered to $119 from $123 at Morgan Stanley
25d ago
KYMR
Premium
The Fly
Kymera Therapeutics reports Q1 EPS (71c), consensus (86c)
26d ago
KYMR
Premium
The Fly
FDA grants fast track designation to Kymera Therapeutics KT-621
1M ago
KYMR
Premium
Ratings
Reaffirming Buy: Kymera’s Protein Degradation Platform and KT-621 Pipeline Advance Underpin Long-Term Value
2M ago
KYMR
Premium
The Fly
Kymera Therapeutics announces Gilead option exercise to license KT-200
2M ago
GILD
KYMR
Premium
The Fly
Kymera Therapeutics presents results from BroADen Phase 1b AD trial of KT-621
2M ago
KYMR
Premium
Company Announcements
Kymera Therapeutics Updates Bylaws on Federal Securities Litigation
2M ago
8K
KYMR
Premium
The Fly
Kymera Therapeutics assumed with a Buy at Jefferies
2M ago
KYMR
Premium
The Fly
Kymera Therapeutics price target raised to $128 from $90 at UBS
3M ago
KYMR
Premium
The Fly
Kymera Therapeutics price target raised to $100 from $95 at Stephens
3M ago
KYMR
Premium
Ratings
Kymera: Expanding Degrader Pipeline and Early Clinical Validation Support Buy Rating and Favorable Risk-Reward
3M ago
KYMR
Premium
The Fly
Kymera Therapeutics price target raised to $120 from $110 at Citi
3M ago
KYMR
Premium
Company Announcements
Kymera Therapeutics Signals Strong Momentum In Earnings Call
3M ago
KYMR
Premium
Company Announcements
Kymera’s KT-579 Enters First-in-Human Testing: What Early Trial Progress Means for Investors
3M ago
KYMR
Premium
Ratings
Kymera Therapeutics: Advancing Differentiated Oral Immunology Assets with Multi-Indication Runway Through 2029
3M ago
KYMR
Premium
The Fly
Kymera Therapeutics price target lowered to $123 from $127 at Morgan Stanley
3M ago
KYMR
Premium
The Fly
Kymera Therapeutics price target raised to $140 from $125 at Piper Sandler
3M ago
KYMR
Premium
Company Announcements
Kymera Therapeutics Establishes New $500 Million ATM Program
3M ago
8K
KYMR
Premium
The Fly
Kymera Therapeutics reports Q4 EPS (97c), consensus (79c)
3M ago
KYMR
Show More
Trending
Indices
Stocks
ETFs
Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >
You need to enable JavaScript to run this app.
